JUNE 24

Both Christina and Stuart were delighted to attend ISCT 2024 in Vancouver. It was fantastic to have the opportunity to connect with experts in the cell and gene therapy field and ...

JUNE 24

Christina represented VascVersa at the panel discussion. It was great to showcase VascVersa and give the audience an insight into...

MAY 24

Fiona was successful in her application for the C-TRIC single-cell competition. Winning this competition funds a multiomic analysis study worth £10K...

MAY 24

Christina was delighted to attend the European Wound Management Association (EWMA) conference in London. This was an excellent conference featuring...

MAY 24

Fiona represented VascVersa at the annual Scotblood conference held at the beautiful University of Stirling.

MAY 24

VascVersa are pleased to announce their success in securing Launchpad NI funding. This funding will allow VascVersa to...

APRIL 2024

This event hosted by HIRANI was held in the beautiful Titanic Building in Belfast in April 2024. It brought together key stakeholders in digital ecosystems, diagnostics and therapeutics...

MARCH 2024

VascVersa attended Advanced Therapies 2024 in London. This event is Europe’s largest commercial cell and gene therapy conference and exhibition....

NOVEMBER 2023

VascVersa took part in the NI Deep Tech Accelerator Programme and presented at the DeepTech Summit in Belfast -November 2023

SEPTEMBER 2023

Christina presented at Inbound Investors. Inbound Investors took place at the Titanic Hotel in Belfast...

AUGUST 2023

VascVersa is delighted to partner with HiTech Health, Galway....

JULY 2023

VascVersa have been awarded Invest NI funding. This support from Invest NI will allow us to strengthen our Angicyte portfolio...

JUNE 2023

Working alongside QUBIS, VascVersa has now moved into a fully operational lab suite comprised of a spacious, main laboratory and two satellite tissue culture suites.

MAY 2023

VascVersa is delighted to work with Alcyomics. The Newcastle based company are highly experienced experts in determining the safety of therapeutic products including advanced cellular therapies.

SEPTEMBER 2022

VascVersa is pleased to announce the addition of Dr Fiona Cunningham to the team!

AUGUST 2022

VascVersa completes second investment round to accelerate development of ground-breaking cell therapies.

MARCH 2022

VascVersa will work with Anthony Nolan Cell & Gene Therapy Services who will support the company by supplying high-quality cord material for VascVersa to facilitate their development of ANGICYTE™ technology.

MARCH 2022

This face to face event supported by Clarendon Fund Managers provided a fantastic opportunity for the team to showcase ANGICYTE™ technology to a local investor network. VascVersa presented...

FEBRUARY 2022

VascVersa leads consortium to advance new cell therapy for the treatment of chronic non-healing wounds.

SEPTEMBER 2020

VascVersa reach regional finals in Intertrade Ireland Seedcorn Competition 2021. This Seedcorn investor readiness competition was a fantastic opportunity for the company to secure expert feedback...

MARCH 2021

VascVersa were awarded a place on a prestigious PULSE programme. This was a three-day leadership and entrepreneurship training programme developed by the BIA and the Francis Crick Institute.

APRIL 2021

Award winning Queen’s University spin out VascVersa has completed a six-figure deal in its first investment round led by QUBIS, with support from Co-Fund NI and a group of angel investors from...

NOVEMBER 2021

VascVersa were excited to attend their first face to face event in 2021 at the beautiful Glenlo Abbey in Galway. This event hosted by HiTech Health was a three-day event featuring international experts...

DECEMBER 2021

VascVersa were delighted to become an NA-ATCC partner. The consortium consists of twenty industry, NHS and academic organisations lead by...